Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IQV
IQV logo

IQV Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
171.000
Open
170.670
VWAP
167.00
Vol
3.70M
Mkt Cap
28.00B
Low
162.220
Amount
618.49M
EV/EBITDA(TTM)
11.98
Total Shares
166.90M
EV
41.86B
EV/OCF(TTM)
15.48
P/S(TTM)
1.73
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments Commercial Solutions and Research & Development Solutions. Commercial Solutions provides information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company's life science clients. Its Research & Development Solutions, which primarily serves biopharmaceutical customers, provides outsourced clinical research, clinical trial and real-world research related services. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company's life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers and provides outsourced clinical research and clinical trial-related services.
Show More

Events Timeline

(ET)
2026-06-11
14:30:00
Jeff Bezos' New AI Venture Prometheus Raises $12B, Valuation Reaches $41B
select
2026-05-13 (ET)
2026-05-13
16:40:00
IQVIA Advances Strategic Collaboration with Kexing Biopharm
select
2026-05-07 (ET)
2026-05-07
17:20:00
Iqvia Authorizes $2B Stock Buyback
select
2026-05-05 (ET)
2026-05-05
07:20:00
Company Reports Q1 Revenue of $4.151B
select
2026-05-05
07:20:00
Sees FY26 Revenue at $17.15B-$17.35B
select

News

seekingalpha
6.0
06-17seekingalpha
Morgan Stanley Upgrades Charles River, Downgrades IQVIA Amid Biopharma Funding Boost
  • Charles River Upgrade: Morgan Stanley upgraded Charles River Laboratories (CRL) from Equal Weight to Overweight, anticipating that increased biopharma funding will drive RFPs and bookings, reflecting market confidence in its preclinical research capabilities.
  • Rising Safety Testing Demand: The analyst noted that while AI may impact the company's discovery activities, the demand for CRL's safety testing is expected to rise significantly as pharma pipelines become smarter, lowering barriers to market entry.
  • IQVIA Downgrade: Morgan Stanley downgraded IQVIA (IQV) from Overweight to Equal Weight and lowered its price target from $225 to $200, primarily due to a lack of clarity on catalysts that could enhance its performance relative to peers.
  • Limited EPS Growth: Although IQVIA's EPS growth since 2022 has largely been driven by share buybacks, the analyst remains cautious about its future sustainable growth, citing uncertainty regarding AI's impact on its narrative.
Newsfilter
2.0
06-15Newsfilter
Wiley and IQVIA Release AI and Science Report
  • Executive Summit Insights: The executive summit co-hosted by Wiley and IQVIA brought together over 25 senior leaders from pharma, academia, and technology to discuss the role of AI in the science-to-patient journey, highlighting the need for cross-sector collaboration.
  • Gap Between AI and Health Systems: The report emphasizes that while AI accelerates every stage from scientific discovery to patient benefit, a significant gap exists between AI's technical capabilities and the health system's ability to absorb these advancements, necessitating structural changes.
  • Five High-Potential Directions: Participants identified five high-potential directions, including decision-first discovery, sharing structured negative data, and deploying patient-facing AI agents, aimed at enhancing the integration of scientific research and clinical application.
  • Challenges of Incentive Structures: The report candidly addresses that existing incentive structures hinder optimization for science, patients, and long-term progress, underscoring the need for collaboration across sectors to achieve necessary structural changes.
Newsfilter
8.5
06-04Newsfilter
IQVIA Prices €950 Million Senior Notes Offering
  • Bond Offering Size: IQVIA's wholly owned subsidiary, IQVIA Inc., has announced a €950 million senior notes offering due in 2033, aimed at refinancing existing debt to optimize its capital structure, thereby reducing financial costs and enhancing liquidity.
  • Interest Rate and Payment Schedule: The notes will bear an interest rate of 4.625% per annum, with interest payments scheduled semi-annually on June 15 and December 15, starting December 15, 2026, ensuring a stable income stream for investors and boosting market confidence in IQVIA.
  • Issuance Timeline and Conditions: The issuance is expected to occur around June 11, 2026, subject to customary closing conditions, providing the company with flexible funding management strategies to support future investments and expansions.
  • Compliance and Market Positioning: The notes are being offered only to persons reasonably believed to be qualified institutional buyers under Rule 144A of the Securities Act, as well as to non-U.S. investors, demonstrating IQVIA's compliance and professionalism in the global capital markets.
seekingalpha
8.5
06-03seekingalpha
IQVIA Plans €950M Senior Notes Offering to Refinance Debt
  • Financing Plan: IQVIA Holdings' wholly-owned subsidiary IQVIA intends to raise €950 million through a senior notes offering due in 2033, aimed at optimizing its capital structure and reducing financial costs.
  • Debt Restructuring: The proceeds from this offering will be used to refinance existing debt and cover related expenses, which is expected to improve the company's financial condition and enhance liquidity, thereby supporting future investments.
  • Market Condition Dependency: The offering is subject to market conditions and customary closing requirements, reflecting the company's cautious approach in the current economic environment, which may impact the timing and scale of the financing.
  • Performance Outlook: In its latest earnings report, IQVIA raised its adjusted EPS outlook for 2026 to between $12.65 and $12.95 while reaffirming its revenue target of $17.15 billion to $17.35 billion, indicating strong confidence in future growth.
Newsfilter
8.5
06-03Newsfilter
IQVIA Plans €950 Million Senior Notes Offering
  • Financing Size: IQVIA intends to raise €950 million through the issuance of senior notes due 2033, aimed at optimizing its existing debt structure, thereby reducing financial costs and enhancing capital flexibility.
  • Use of Proceeds: The proceeds from this notes offering will be used to refinance existing debt and cover related expenses, which is expected to improve the company's financial condition and provide funding for future investments.
  • Market Condition Dependency: The consummation of the notes offering is subject to market and other customary conditions, indicating the company's sensitivity to capital markets and its ability to respond flexibly in the current economic environment.
  • Compliance Statement: This notes offering does not constitute an offer to sell in any state or jurisdiction where such an offer would be unlawful, reflecting the company's strict compliance awareness with securities laws.
Yahoo Finance
8.5
06-03Yahoo Finance
IQVIA Plans €950 Million Senior Notes Offering
  • Financing Size: IQVIA Holdings Inc. plans to issue €950 million in senior notes through its wholly owned subsidiary, maturing in 2033, aimed at optimizing existing debt and covering related expenses, thereby enhancing financial flexibility.
  • Market Condition Dependency: The completion of this notes offering is subject to market and other customary conditions, reflecting the company's cautious approach to financing in the current economic environment, which may impact short-term capital liquidity.
  • Compliance Statement: The notes have not been registered under the Securities Act of 1933 and are offered only to persons reasonably believed to be qualified institutional buyers, ensuring adherence to relevant laws and reducing compliance risks.
  • Global Business Context: As a leading global provider of clinical research services, IQVIA employs approximately 93,000 people and is committed to accelerating the development and commercialization of innovative medical treatments through high-quality health data and advanced analytics, further solidifying its market position in the life sciences sector.
Wall Street analysts forecast IQV stock price to rise
15 Analyst Rating
Wall Street analysts forecast IQV stock price to rise
12 Buy
3 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
215.00
Averages
258.31
High
290.00
Current: 0.000
sliders
Low
215.00
Averages
258.31
High
290.00
Morgan Stanley
Kallum Titchmarsh
Overweight -> Equal Weight
downgrade
$225 -> $200
AI Analysis
2026-06-17
New
Reason
Morgan Stanley
Kallum Titchmarsh
Price Target
$225 -> $200
AI Analysis
2026-06-17
New
downgrade
Overweight -> Equal Weight
Reason
Morgan Stanley analyst Kallum Titchmarsh downgraded Iqvia (IQV) to Equal Weight from Overweight with a price target of $200, down from $225. The firm struggles to identify "clear drivers of upside" for Iqvia relative to the Charles River (CRL) setup, says the analyst, who also is "somewhat skeptical" on margin expansion from today's levels.
HSBC
Buy
to
Buy
downgrade
$240 -> $210
2026-06-03
Reason
HSBC
Price Target
$240 -> $210
2026-06-03
downgrade
Buy
to
Buy
Reason
HSBC lowered the firm's price target on Iqvia to $210 from $240 and keeps a Buy rating on the shares. The firm says market expectations on life science tools "remain bearish" with allocation tilted towards managed care and therapeutics within healthcare. While the tools sector is priced for disappointment, HSBC sees "green shoots of recovery," notably in bioprocessing and quality assurance, the analyst tells investors in a research note. The firm adjusted target prices to reflect risk-adjusted return expectations. HSBC's preferred ideas are Waters, Iqvia, and Sartorius.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IQV
Unlock Now

Valuation Metrics

The current forward P/E ratio for IQVIA Holdings Inc (IQV.N) is 13.12, compared to its 5-year average forward P/E of 19.57. For a more detailed relative valuation and DCF analysis to assess IQVIA Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
19.57
Current PE
13.12
Overvalued PE
23.36
Undervalued PE
15.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
14.05
Current EV/EBITDA
11.52
Overvalued EV/EBITDA
16.48
Undervalued EV/EBITDA
11.61

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.51
Current PS
1.53
Overvalued PS
3.03
Undervalued PS
1.98

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

top high conviction u.s. stocks
Intellectia · 18 candidates
Market Cap: >= 10.00BRegion: USAnalyst Consensus: Strong BuyPe Ttm: <= 25List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Is Index Component: GSPC, NDX, DJI, RUTFree Cash Flow Ttm: >= 0
Ticker
Name
Market Cap$
top bottom
SCHW logo
SCHW
Charles Schwab Corp
158.44B
UBER logo
UBER
Uber Technologies Inc
140.15B
NEM logo
NEM
Newmont Corporation
107.00B
RCL logo
RCL
Royal Caribbean Cruises Ltd
78.95B
CI logo
CI
Cigna Group
78.83B
B logo
B
Barrick Mining Corp
67.35B
best stocks for June
Intellectia · 22 candidates
Market Cap: >= 2.00BRevenue Ttm: >= 0Analyst Consensus: Strong Buy, Moderate BuyEps Ttm: >= 0Quarter Eps Yoy Growth: >= 0.0%Rsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Month Price Change Pct: >= $0.00News Driver: Positive
Ticker
Name
Market Cap$
top bottom
NBIX logo
NBIX
Neurocrine Biosciences, Inc
16.60B
BTSG logo
BTSG
Brightspring Health Services Inc
11.81B
TER logo
TER
Teradyne Inc
64.13B
QCOM logo
QCOM
Qualcomm Inc
263.51B
LLY logo
LLY
Eli Lilly and Co
1.02T
GLW logo
GLW
Corning Inc
172.78B
give me a good stock rn for a fressh entry
Intellectia · 7 candidates
Market Cap: >= 1000.00MAnalyst Consensus: Strong Buy, Moderate BuyRsi Category: moderateRelative Vol: >= 1.50Analyst Action: UpgradeMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Macd: positive, bullishNews Driver: Positive
Ticker
Name
Market Cap$
top bottom
IQV logo
IQV
IQVIA Holdings Inc
29.44B
DORM logo
DORM
Dorman Products Inc
3.57B
CMI logo
CMI
Cummins Inc
93.13B
BWA logo
BWA
Borgwarner Inc
11.80B
AEP logo
AEP
American Electric Power Company Inc
74.56B
WMB logo
WMB
Williams Companies Inc
93.09B
what stock to night trade tonight
Intellectia · 87 candidates
Market Cap: >= 50.00MVolume: >= 100,000Price Change Pct: $-100.00 - $100.00Analyst Action: UpgradeMoving Average Relationship: PriceAboveMA20, PriceBelowMA20Is Optionable: TrueMonthly Average Dollar Volume: >= 100,000News Driver: Positive
Ticker
Name
Market Cap$
top bottom
DOCN logo
DOCN
DigitalOcean Holdings Inc
15.94B
FTRE logo
FTRE
Fortrea Holdings Inc
1.37B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.72B
INTC logo
INTC
Intel Corp
543.56B
ECG logo
ECG
Everus Construction Group Inc
8.59B
SEAT logo
SEAT
Vivid Seats Inc
78.67M
which 5 stocks are a strong buy today
Intellectia · 59 candidates
Market Cap: >= 5.00BRegion: USQuarter Revenue Yoy Growth: >= 10.0%Analyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceShares Outstanding: >= 0One Month Predict Return: >= 0.0%
Ticker
Name
Market Cap$
top bottom
BROS logo
BROS
Dutch Bros Inc
8.30B
FUTU logo
FUTU
Futu Holdings Ltd
19.64B
STN logo
STN
Stantec Inc
10.05B
MCO logo
MCO
Moody's Corp
79.05B
NTNX logo
NTNX
Nutanix Inc
10.48B
MSFT logo
MSFT
Microsoft Corp
2.77T
busca mejor compra en este momento
Intellectia · 14 candidates
Analyst Consensus: Strong BuyEps 5yr Cagr: >= 10Pe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePrice, AbovePriceMoving Average Relationship: PriceAboveMA20Is Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
NXPI logo
NXPI
NXP Semiconductors NV
49.16B
IQV logo
IQV
IQVIA Holdings Inc
29.08B
GOOG logo
GOOG
Alphabet Inc
3.56T
RL logo
RL
Ralph Lauren Corp
21.07B
AMZN logo
AMZN
Amazon.com Inc
2.25T
NUE logo
NUE
Nucor Corp
39.28B
what are the best stocks right now
Intellectia · 72 candidates
Region: USAnalyst Consensus: Strong Buy, Moderate BuyEps 5yr Cagr: >= 10Pe Ttm: 10 - 35Return On Equity: >= 15.0%Is Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
SCHW logo
SCHW
Charles Schwab Corp
166.86B
GILD logo
GILD
Gilead Sciences Inc
178.68B
NXPI logo
NXPI
NXP Semiconductors NV
50.98B
WMB logo
WMB
Williams Companies Inc
90.69B
SYY logo
SYY
Sysco Corp
40.82B
IQV logo
IQV
IQVIA Holdings Inc
29.29B
rsi below 35 in the s&p500
Intellectia · 22 candidates
Rsi Category: oversoldIs Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
TMO logo
TMO
Thermo Fisher Scientific Inc
192.95B
CRM logo
CRM
Salesforce Inc
175.96B
ACN logo
ACN
Accenture PLC
147.75B
BKNG logo
BKNG
Booking Holdings Inc
137.64B
PANW logo
PANW
Palo Alto Networks Inc
124.32B
INTU logo
INTU
Intuit Inc
108.41B
what best stock to buy right now??
Intellectia · 92 candidates
Market Cap: >= 20.00BNet Margin: >= 10.00Eps 5yr Cagr: >= 10Pe Ttm: 10 - 35List Exchange: XNYS, XNASIs Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
SCHW logo
SCHW
Charles Schwab Corp
169.48B
BKNG logo
BKNG
Booking Holdings Inc
137.64B
GILD logo
GILD
Gilead Sciences Inc
189.55B
NXPI logo
NXPI
NXP Semiconductors NV
59.73B
KMI logo
KMI
Kinder Morgan Inc
71.84B
WFC logo
WFC
Wells Fargo & Co
273.88B
Best stocks to buy today
Intellectia · 6 candidates
Market Cap: >= 20.00BAnalyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.66T
PCG logo
PCG
PG&E Corp
36.05B
AVGO logo
AVGO
Broadcom Inc
1.65T
AMD logo
AMD
Advanced Micro Devices Inc
352.35B
MDB logo
MDB
MongoDB Inc
29.34B
IQV logo
IQV
IQVIA Holdings Inc
31.80B

Whales Holding IQV

C
Cornerstone Investment Partners, LLC
Holding
IQV
+31.69%
3M Return
I
Inspire Investing, LLC
Holding
IQV
+26.00%
3M Return
L
LGPS Central Limited
Holding
IQV
+23.74%
3M Return
A
Appaloosa Management L.P.
Holding
IQV
+20.15%
3M Return
H
Heritage Investors Management Corp
Holding
IQV
+18.75%
3M Return
C
Community Trust and Investment Company
Holding
IQV
+16.51%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is IQVIA Holdings Inc (IQV) stock price today?

The current price of IQV is 167.77 USD — it has decreased -1.7

What is IQVIA Holdings Inc (IQV)'s business?

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments Commercial Solutions and Research & Development Solutions. Commercial Solutions provides information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company's life science clients. Its Research & Development Solutions, which primarily serves biopharmaceutical customers, provides outsourced clinical research, clinical trial and real-world research related services. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company's life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers and provides outsourced clinical research and clinical trial-related services.

What is the price predicton of IQV Stock?

Wall Street analysts forecast IQV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IQV is258.31 USD with a low forecast of 215.00 USD and a high forecast of 290.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is IQVIA Holdings Inc (IQV)'s revenue for the last quarter?

IQVIA Holdings Inc revenue for the last quarter amounts to 4.15B USD, increased 8.41

What is IQVIA Holdings Inc (IQV)'s earnings per share (EPS) for the last quarter?

IQVIA Holdings Inc. EPS for the last quarter amounts to 1.61 USD, increased 15.00

How many employees does IQVIA Holdings Inc (IQV). have?

IQVIA Holdings Inc (IQV) has 93000 emplpoyees as of June 20 2026.

What is IQVIA Holdings Inc (IQV) market cap?

Today IQV has the market capitalization of 28.00B USD.